WO2007103521A3 - Preventing norvaline and norleucine misincorporation in recombinant proteins - Google Patents

Preventing norvaline and norleucine misincorporation in recombinant proteins Download PDF

Info

Publication number
WO2007103521A3
WO2007103521A3 PCT/US2007/005963 US2007005963W WO2007103521A3 WO 2007103521 A3 WO2007103521 A3 WO 2007103521A3 US 2007005963 W US2007005963 W US 2007005963W WO 2007103521 A3 WO2007103521 A3 WO 2007103521A3
Authority
WO
WIPO (PCT)
Prior art keywords
norvaline
preventing
recombinant proteins
norleucine misincorporation
misincorporation
Prior art date
Application number
PCT/US2007/005963
Other languages
French (fr)
Other versions
WO2007103521A2 (en
Inventor
Andrew C Macdonald
Nicholas Abu-Absi
Duane Inlow
Mary Poulhzan
Original Assignee
Novartis Ag
Andrew C Macdonald
Nicholas Abu-Absi
Duane Inlow
Mary Poulhzan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Andrew C Macdonald, Nicholas Abu-Absi, Duane Inlow, Mary Poulhzan filed Critical Novartis Ag
Priority to EP07752647A priority Critical patent/EP1996697A2/en
Publication of WO2007103521A2 publication Critical patent/WO2007103521A2/en
Publication of WO2007103521A3 publication Critical patent/WO2007103521A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Sampling And Sample Adjustment (AREA)

Abstract

Methods of preventing norvaline and norleucine misincorporation in recombinant proteins.
PCT/US2007/005963 2006-03-07 2007-03-07 Preventing norvaline and norleucine misincorporation in recombinant proteins WO2007103521A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07752647A EP1996697A2 (en) 2006-03-07 2007-03-07 Preventing norvaline and norleucine misincorporation in recombinant proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77942906P 2006-03-07 2006-03-07
US60/779,429 2006-03-07

Publications (2)

Publication Number Publication Date
WO2007103521A2 WO2007103521A2 (en) 2007-09-13
WO2007103521A3 true WO2007103521A3 (en) 2008-02-21

Family

ID=38475570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/005963 WO2007103521A2 (en) 2006-03-07 2007-03-07 Preventing norvaline and norleucine misincorporation in recombinant proteins

Country Status (2)

Country Link
EP (1) EP1996697A2 (en)
WO (1) WO2007103521A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3597659T (en) 2007-07-09 2023-05-10 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
JP6479661B2 (en) * 2012-09-19 2019-03-06 ジェネンテック， インコーポレイテッド Methods and compositions for preventing norleucine misincorporation into proteins
JP2022514083A (en) * 2018-12-20 2022-02-09 サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング How to reduce misuptake of non-canonical branched chain amino acids
WO2024079114A1 (en) 2022-10-11 2024-04-18 UCB Biopharma SRL Process for the production of recombinant proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037475A1 (en) * 2003-08-13 2005-02-17 Chiron Corporation Method of purifying TFPI and TFPI analogs
WO2005038017A2 (en) * 2003-09-25 2005-04-28 Monsanto Technology Llc Prevention of incorporation of non-standard amino acids into protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037475A1 (en) * 2003-08-13 2005-02-17 Chiron Corporation Method of purifying TFPI and TFPI analogs
WO2005038017A2 (en) * 2003-09-25 2005-04-28 Monsanto Technology Llc Prevention of incorporation of non-standard amino acids into protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
APOSTOL IZYDOR ET AL: "Incorporation of norvaline at leucine positions in recombinant human hemoglobin expressed in Escherichia coli", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 46, 14 November 1997 (1997-11-14), pages 28980 - 28988, XP002461320, ISSN: 0021-9258 *
BOGOSIAN G ET AL: "Biosynthesis and incorporation into protein of norleucine by Escherichia coli", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 264, no. 1, 5 January 1989 (1989-01-05), pages 531 - 539, XP002324310, ISSN: 0021-9258 *
TSAI L B ET AL: "CONTROL OF MISINCORPORATION OF DE-NOVO SYNTHESIZED NORLEUCINE INTO RECOMBINANT INTERLEUKIN-2 ESCHERICHIA-COLI", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 156, no. 2, 1988, pages 733 - 739, XP009093276, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2007103521A2 (en) 2007-09-13
EP1996697A2 (en) 2008-12-03

Similar Documents

Publication Publication Date Title
EP2102355A4 (en) Long acting proteins and peptides and methods of making and using the same
IL250938A0 (en) Enzymatic fusion proteins, compositions comprising the same and uses thereof
EP1713440A4 (en) Engineered proteins, and methods of making and using
EP2007884A4 (en) Enzyme fusion proteins and their use
EP2012808A4 (en) Extracts and methods comprising ganoderma species
WO2009100255A3 (en) Modified leptin polypeptides and their uses
WO2008030558A3 (en) Modified human plasma polypeptide or fc scaffolds and their uses
EP2029799A4 (en) Thermostable proteins and methods of making and using thereof
WO2009067636A3 (en) Modified insulin polypeptides and their uses
IL179589A0 (en) Injection port and method of making the same
IL197094A0 (en) Immunogenic pcpa polypeptides and uses thereof
WO2009130584A3 (en) Use of surfactant in the ~preparation of modified sulfur and sulfur cement
AU2013201592A1 (en) Improved vaccines and methods for using the same
WO2008008857A3 (en) Thiolated macromolecules and methods of making and using thereof
WO2010011735A3 (en) Modified bovine g-csf polypeptides and their uses
WO2009036460A3 (en) Modified human apolipoprotein a-i polypeptides and their uses
WO2005082020A3 (en) Flavivirus vaccines
EP2246064A4 (en) Recombinant ganoderma lucidium immunomodulatory protein (rlz-8) and uses thereof
PL2118134T3 (en) Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof
EP2010645A4 (en) Recombinant lactobacillus and use of the same
GB0615635D0 (en) Immunogenic proteins and uses thereof
IL195525A0 (en) Replikin peptides and uses thereof
WO2007103521A3 (en) Preventing norvaline and norleucine misincorporation in recombinant proteins
IL198659A (en) Targeting signals and recombinant proteins containing them
GB0604187D0 (en) Peptide and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007752647

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE